Neurocrine Biosciences (NBIX) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Neurocrine Bio. (NBIX) PT Raised to $138 at Stifel; Nice Ingrezza Beat and Better TRx Commentary
August 3, 2021 5:54 PM EDTStifel analyst Paul Matteis raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $138.00 (from $136.00) while maintaining a Buy rating following results.
The analyst commented, "We are reiterating our Buy rating on NBIX on the back of a solid 2Q for... More

